Two roads to growth hormone. One is the community's default anti-aging stack. The other is the only peptide the FDA has approved specifically for visceral fat.
Bottom line: These are not competing for the same customer. CJC-1295 (no DAC) + ipamorelin stacks two complementary mechanisms , GHRH receptor stimulation plus ghrelin receptor activation , to produce a more natural, pulsatile GH release than either can achieve alone. That multi-pathway push is why it became the default GH stack at anti-aging clinics: broad benefits across sleep, recovery, body composition, and skin with a manageable side-effect profile. Tesamorelin is a one-target tool. Its Phase 3 data in 806 HIV patients showed a 15.4% reduction in visceral adipose tissue at 26 weeks , the only peptide with that specific clinical evidence. The trade-off: it's expensive (typically $1,200–1,800/month through a prescribing clinic), the EMA declined to approve it (FDA-only), and it does almost nothing for sleep, recovery, or the other goals CJC/Ipa covers. Pick the stack for broad GH support; pick tesamorelin when visceral fat is the precise, isolated target and you want real clinical data behind the decision.
| CJC-1295 / Ipamorelin | Tesamorelin | |
|---|---|---|
| What it actually is | Two peptides used together: CJC-1295 (no DAC) hits GHRH receptors; ipamorelin hits ghrelin receptors. Dual-pathway GH pulse. | GHRH(1-44) stabilized with a trans-3-hexenoic acid group. Single-pathway, single daily dose. Branded as Egrifta. |
| Mechanism | GHRH-receptor stimulation + ghrelin-receptor (GHS-R) activation in combination. Synergistic , each amplifies the other's signal. Result: larger, cleaner GH pulses without cortisol or prolactin bleed. | Direct GHRH receptor agonism only. Stimulates the pituitary to release GH endogenously. No ghrelin pathway. No synergistic effect. |
| Half-life | CJC-1295 (no DAC): ~30 min. Ipamorelin: ~2 hours. Both are short , that's the point. They trigger a pulse and clear. | 26–38 minutes. Also short; acts at the pituitary and is cleared quickly. Bioavailability is ≤4% (hence the daily sub-Q injection). |
| Reported dose | CJC-1295 (no DAC): 100–300 mcg. Ipamorelin: 100–300 mcg. Usually equal parts, same syringe, once or twice daily. | 2 mg subcutaneous injection once daily. This is the FDA-approved dose , no titration. |
| Frequency | 1–2x daily. Most run it once before bed to amplify the natural nocturnal GH pulse. Some run a morning injection on training days. | Once daily, recommended in the evening on an empty stomach. No dosing flexibility in the approved label. |
| Primary clinical evidence | CJC-1295 with DAC: Phase 2 PK data, 65 subjects (PMID 16822960). Ipamorelin: preclinical selectivity data (PMID 9849822). The no-DAC + ipamorelin combination: no dedicated RCT. | Two Phase 3 RCTs pooled, 806 HIV patients with lipodystrophy. −15.4% visceral fat at 26 weeks; −17.5% at 52 weeks. FDA-approved 2010. EMA withdrew in 2012 (no EU approval). |
| Top side effects | Water retention (especially early). Mild tingling or numbness in the hands. Vivid dreams during the first 2–4 weeks. Headache on higher doses. | Injection site reactions (~30%): redness, itching, swelling. Joint and muscle pain from rapid fat redistribution. Peripheral edema. IGF-1 elevation (monitored with labs). |
| IGF-1 impact | Modest elevation , follows the GH pulse and normalizes between doses. Labs not usually required but monitored in clinical protocols. | Sustained IGF-1 elevation with daily dosing. The EMA flagged IGF-1 rise in 'a considerable number of patients' as a safety concern. Monitoring is standard in prescribing protocols. |
| Common vial size | CJC-1295 (no DAC): 2 mg or 5 mg. Ipamorelin: 5 mg. Often sold as a pre-blended vial (e.g., 3 mg CJC + 3 mg Ipa). | 2 mg single-dose vial (Egrifta). 2.4 mg formulation also available (Egrifta SV, simplified reconstitution). |
| Approval status | Not FDA-approved for any use. Category 1 compound (503A/503B compounding list, updated Feb 2026) , means it can be dispensed by compounding pharmacies with a valid prescription. | FDA-approved as Egrifta for HIV-associated lipodystrophy with excess abdominal fat. Prescription required. Not approved in the EU (EMA withdrawal, 2012). |
| Who uses it | Anti-aging and longevity clinics (most common GH support stack). Bodybuilders in the off-season. People 35+ optimizing sleep and recovery. | HIV patients with lipodystrophy under physician supervision. Off-label at longevity/metabolic clinics for visceral fat reduction in non-HIV patients. |
| Monthly cost (approx.) | ~$80–120/month through research-grade or compounding sources. Much lower cost than any prescription GH pathway. | ~$1,200–1,800/month through prescribing clinics. Occasionally lower with manufacturer programs; not available OTC. |
tierA: {"tier":2,"label":"Emerging evidence"}
tierB: {"tier":1,"label":"FDA-approved , completed Phase 3"}
summary: CJC-1295 (no DAC) has pharmacokinetic data in humans and ipamorelin has Phase 2 data, but the combination is clinic-derived rather than trial-validated. Tesamorelin has two completed Phase 3 RCTs, FDA approval since 2010, and a pooled analysis in 806 patients. The EMA withdrew the application in 2012 citing lack of demonstrated clinical benefit beyond fat reduction itself.
trials: [{"name":"CJC-1295 Phase 2 pharmacokinetics (human)","peptide":"a","n":"65","finding":"Single dose increased GH by 2–10x for ≥6 days and IGF-1 by 0.5–3x for 9–11 days. Multiple doses maintained elevated IGF-1 for up to 28 days. Study used CJC-1295 with DAC; community protocol uses the no-DAC form for pulsatile dosing.","pmid":"16822960","citation":"Ionescu M, Frohman LA. Pituitary. 2006."},{"name":"Ipamorelin GH selectivity (rat/dog)","peptide":"a","n":"animal","finding":"Ipamorelin produced GH release comparable to GHRP-6 with no significant ACTH, cortisol, or prolactin response , establishing its selectivity advantage over earlier GHRPs.","pmid":"9849822","citation":"Raun K et al. Eur J Endocrinol. 1998."},{"name":"Tesamorelin Phase 3 pooled analysis (HIV lipodystrophy)","peptide":"b","n":"806","finding":"2 mg/day SC for 26 weeks reduced visceral adipose tissue by 15.4% vs +0.6% placebo (−24 ± 41 vs +2 ± 35 cm²). At 52 weeks, VAT reduction sustained at 17.5%. No clinically meaningful glucose changes observed.","pmid":"20554713","citation":"Falutz J et al. J Clin Endocrinol Metab. 2010;95(9):4291–4304."},{"name":"Tesamorelin triglyceride and body image effects","peptide":"b","n":"806","finding":"Alongside VAT reduction, tesamorelin significantly lowered triglycerides and improved patient-reported body image distress scores , secondary endpoints from the same pooled Phase 3 dataset.","pmid":"20554713","citation":"Falutz J et al. J Clin Endocrinol Metab. 2010."}]
{"applies":true,"name":"Tesamorelin + Ipamorelin","intro":"Some advanced users and longevity physicians stack tesamorelin with ipamorelin to add a ghrelin-receptor signal to tesamorelin's GHRH effect , the same logic as running CJC/Ipa, but with tesamorelin in the GHRH seat. This is off-label and adds cost, but the pharmacological rationale is the same: dual-pathway GH stimulation produces larger pulses than single-pathway alone.","phases":[{"name":"Tesamorelin base","detail":"2 mg tesamorelin daily, evening, empty stomach , as per standard protocol"},{"name":"Ipamorelin add-on","detail":"100–200 mcg ipamorelin, same evening injection, timed with tesamorelin"}],"note":"Not validated in trials. Adding ipamorelin to tesamorelin is off-label. If cost is a concern, CJC-1295 (no DAC) + ipamorelin achieves the same dual-pathway goal at a fraction of the price. Tesamorelin + ipamorelin is a niche protocol used when the clinician wants tesamorelin's specific visceral fat evidence plus a ghrelin-pathway amplifier."}
Physicians can prescribe it off-label , HIV diagnosis is not required to write a prescription. Some longevity and metabolic clinics do prescribe tesamorelin for non-HIV visceral fat reduction. But you are paying for a drug approved for a different population, and the clinical evidence was generated in HIV patients with lipodystrophy (a specific fat redistribution syndrome). The mechanism works regardless of HIV status; the data just does not come from a general-population trial.
The two hit different receptors. CJC-1295 (no DAC) stimulates GHRH receptors on the pituitary , it tells the pituitary to make GH. Ipamorelin hits ghrelin receptors (GHS-R) , it amplifies the release signal. When you run them together, the pulse is significantly larger than either alone. It is the same logic behind why ipamorelin is sometimes added to tesamorelin: dual pathway, bigger pulse.
DAC (Drug Affinity Complex) is a modification that lets CJC-1295 bind to albumin, extending its half-life from ~30 minutes to 6–8 days. CJC-1295 with DAC creates a continuous GH elevation, sometimes called a 'GH bleed.' The no-DAC version (also called Modified GRF 1-29) mimics a natural pulse and clears quickly. The community preference , and what most clinics use , is the no-DAC version because sustained GH elevation can blunt the pituitary's sensitivity over time.
In the Phase 3 trials, patients averaged a 24 cm² reduction in visceral adipose tissue cross-section (measured by CT scan) against a 2 cm² increase in the placebo group over 26 weeks. Visceral fat is internal , you cannot see it in the mirror the way subcutaneous fat appears. Patients in the trials reported improvements in body image and waist circumference, but this is not the same as a visible 'six pack.' The effect is metabolic and internal.
The European Medicines Agency reviewed the same Phase 3 data and found the visceral fat reduction , while statistically significant , was not demonstrated to be 'clinically meaningful' in terms of actual health outcomes (cardiovascular events, mortality). They also flagged the IGF-1 elevation as a safety concern without long-term data, and noted the study population (US HIV patients) did not represent the European HIV population, which had lower BMI and less abdominal fat on average. The application was withdrawn in June 2012 before a formal rejection vote.
Not required, but strongly recommended. Baseline IGF-1, fasting glucose, and HbA1c are the standard pre-protocol checks at any competent anti-aging clinic. IGF-1 is the key number , if you start with elevated IGF-1 (above range for your age and sex), GH secretagogues can push it higher, and sustained supraphysiological IGF-1 is a theoretical cancer risk. Recheck at 3 months.
Some physicians do use tesamorelin plus ipamorelin together, replacing CJC with tesamorelin in the GHRH seat. There is no trial data on this combination and the cost is significant (tesamorelin alone is $1,200+ per month). If the goal is dual-pathway GH stimulation, CJC/Ipa achieves the same pharmacological logic at a fraction of the cost. Stacking tesamorelin with CJC/Ipa would be redundant , both CJC and tesamorelin act on the GHRH receptor.
Not meaningfully. The clinical data focuses entirely on visceral fat reduction, triglycerides, and body image. Tesamorelin raises IGF-1 and GH, which are anabolic, but the trials were not designed to measure lean mass gains and did not show significant muscle effects. If muscle preservation or growth is the goal, CJC/Ipa is a better fit because the protocol is optimized for the nocturnal GH pulse that drives tissue repair and lean mass retention.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
